Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Tipranavir/Ritonavir on Carbamazepine PK
NCT02253849Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2005
- Primary completion
- Jun 2006
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of tipranavir in human immunodeficiency virus infection (HIV), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of Carbamazepine in plasma over the time interval t0h to t12h, Maximum measured concentration of Carbamazepine in plasma and 1 more. Started Nov 2005; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02253849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253849.